Applied Therapeutics to Present at the UBS Global Healthcare Conference
Applied Therapeutics (Nasdaq: APLT) announced its participation at the UBS Global Healthcare Conference, scheduled for May 18, 2020, at 10:00 a.m. ET in a virtual format. The event will be accessible via a webcast on the company’s website, with a replay available afterward.
The company specializes in developing novel drug candidates for high unmet medical needs, including AT-007 for Galactosemia and AT-001 for Diabetic Cardiomyopathy. Their preclinical pipeline includes AT-003 for diabetic retinopathy and dual PI3k inhibitors for oncology.
- None.
- None.
NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at the UBS Global Healthcare Conference on Monday, May 18, 2020 at 10:00 a.m. ET. The conference will be held in a virtual meeting format.
Webcast information for this event will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website at www.appliedtherapeutics.com. A replay will also be available following the webcast.
About Applied Therapeutics Inc.
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, AT-007, is a novel central nervous system penetrant aldose reductase inhibitor (ARI) for the treatment of Galactosemia, a rare pediatric metabolic disease. The Company initiated a Phase 1/2 clinical trial in June 2019, read out positive top-line biomarker data in adult Galactosemia patients in January 2020 and announced full data from the trial in April 2020. The Company is also developing AT-001, a novel potent ARI that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The Company initiated a Phase 3 registrational study in DbCM in September 2019. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy, expected to advance into a Phase 1 study in 2020, as well as novel dual PI3k inhibitors in preclinical development for orphan oncology indications.
Investors:
Maeve Conneighton
(212) 600-1902 or
appliedtherapeutics@argotpartners.com
Media:
Gleb Sagitov
media@appliedtherapeutics.com
FAQ
When will Applied Therapeutics present at the UBS Global Healthcare Conference?
How can I access the webcast for the UBS Global Healthcare Conference presentation by Applied Therapeutics?
What drug candidates is Applied Therapeutics developing?
What stage is the clinical trial for AT-007?
What is the focus of the preclinical pipeline at Applied Therapeutics?
